~~<i id='04E5CBE50C'><strike id='04E5CBE50C'><tt id='04E5CBE50C'><pre id='04E5CBE50C'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

fashion

author：knowledge 2025-09-03 15:26:05 - browse：481

Acadia Pharmaceuticals said Monday that its approved medicine called Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial.

The negative outcome of the Phase 3 study represents a setback in the company’s efforts to expand the use of Nuplazid into the treatment of schizophrenia. The medicine is currently approved to treat hallucinations and delusions associated with Parkinson’s disease psychosis.

“We are disappointed the trial did not meet its primary endpoint given the significant unmet need in patients with negative symptoms of schizophrenia,” said Acadia CEO Steve Davis, in a statement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Asbestos, a deadly carcinogen, banned by EPA

focus

explore

focus

hotspot

entertainment

Packetsofbuprenorphine,usedtotreatopioidusedisorder.Asmalltrialfoundreducedcravingswhenthisdrugwaspa

WSS

Flagship Pioneering startup Sonata Therapeutics lays off 21

New CMS data security rules will hurt Medicare, Medicaid research

Nurses recount patients attacks

Gene editing the human germline: What are the risks?

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Positive childhood experiences can help future health

hotspot

fashion

focus

Affirmative action in medical school literally saved lives

Intermittent fasting comes with a heart risk? Not so fast

Peter Hotez and the public health issue of online harassment

Physicians and social media: If you see something, say something?

How to save PrEP access — and even expand it

Baby aspirin cuts fat buildup in liver disease patients, in small study

Novavax promises a turnaround & Lilly roils the obesity market

Hospitals are piloting generative AI tools as regulators play catch

The high cost of giving birth even with insurance

Medicare Advantage enrollment hits roughly 33.4 million

explore

Leading voice in opioid treatment defends methadone clinic system

Hospitals are piloting generative AI tools as regulators play catch

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Positive childhood experiences can help future health

New CMS data security rules will hurt Medicare, Medicaid research

As AI regulations shape up, health tech startups beg for clarity

focus

focus

hotspot

entertainment